Allmed Medical(SZ:002950) Sou Hu Cai Jing·2025-06-13 01:45Core Viewpoint - The company emphasizes its commitment to long-term shareholder value despite recent stock price declines, highlighting its strong market position and strategic initiatives to enhance market share both domestically and internationally [2][4]. Financial Performance - For the fiscal year 2024, the company reported overseas revenue of 2.76 billion yuan, a year-on-year increase of 23.43%, accounting for 82.87% of total revenue [3]. - Domestic revenue for 2024 was 569.79 million yuan, up 8.86%, representing 17.13% of total revenue [3]. - Cumulative cash dividends from 2018 to 2024 amounted to approximately 1.099 billion yuan, which is 2.29 times the net raised funds [2][4]. Market Strategy - The company has maintained its position as the leading exporter in China's medical dressing industry for 17 consecutive years since 2008 [3]. - The company is focusing on expanding its market share in both established and emerging markets, with a strategic emphasis on e-commerce, OTC markets, and hospital professional markets [3][5]. - Future product development will focus on four categories: surgical and wound care, infection protection, advanced dressings, and hygiene care products [6][7]. Product Development - The company is enhancing its product competitiveness and service levels to meet strong customer demand and expand its market share in overseas markets [3]. - Advanced dressing products launched in 2024 include soft silicone foam dressings, hydrocolloid dressings, transparent dressings, and silicone gel scar patches, aimed at chronic and acute wound care [6]. - The hygiene care product line, including sterilized sanitary pads, is in its early stages but has significant growth potential in the large Chinese market [7].